Company Urges Stockholders to Vote ‘FOR’ Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has filed a supplement to its proxy statement for its Annual Meeting. The board of directors approved the following two items, if Proposal #2 passes: The current authorized n

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on ketamine for unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has extended the approval goal date for the review of its new drug application for ketamine. The new approval goal date is August 9, 2025, revised from the previous date of June 4, 2025. The extension allows the FDA additional time

Automated Endoscopic Approach Evaluated for Patients with Obesity, Hypertension, and Type 2 Diabetes CAESAREA, Israel, May 16, 2025 /PRNewswire/ -- Nitinotes, developer of EndoZip™, a fully automated endoscopic suturing system aimed at treating obesity, announced that new interim clinical data was presented at the IFSO-EC 2025 Congress (International Federation for the Surgery of Obesity and Metabolic Disorders) in Venice, Italy. The interim results reflect data from one of several participati

TUSTIN, Calif., May 16, 2025 /PRNewswire/ -- Pangea Laboratory, a leader in the development of advanced cancer diagnostics and microbiome Next-Generation Sequencing (NGS) testing, is proud to announce the appointment of John Moore as its new Chief Executive Officer. Mr. Moore brings with him 25 years of proven success in commercial and operational leadership across the pharmaceutical and diagnostic laboratory industries. His career has taken him from sales representative to executive roles, giv

The treatment will be focused on sensorineural hearing loss, which is the most common cause of hearing loss. \n Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss.The centerpiece of the agreement is Rznomics’ trans-splicing ribozyme platform, which the Seongham, South Korea-based company has touted as enabling “precise RNA editing and has broad applicability across multiple indication

Partnership will build a global AI-powered healthcare platform to deliver more effective, scalable, and affordable care ABU DHABI, United Arab Emirates, May 16, 2025 /PRNewswire/ -- Oracle Health, Cleveland Clinic, and G42 today announced a strategic partnership to develop a groundbreaking AI-based healthcare delivery platform. This initiative aims to improve patient care and public health management by leveraging AI, nation-scale data analytics, and intelligent clinical applications to create s

RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE showing significant and sustained reductions in HAE attack rates through 18 months of follow-up after beginning treatment with ORLADEYO in both patient populations. The real-world evidence was presented in two posters at the 2025 International Societ

New studies presented at the American Thoracic Society (ATS) Conference this week validate e-Lung as an accurate tool to identify progressive pulmonary fibrosis OXFORD, England and CHICAGO, May 16, 2025 /PRNewswire/ -- Brainomix, a company pioneering AI-powered imaging solutions in lung fibrosis and stroke, will be presenting new evidence next week at the American Thoracic Society (ATS) Conference in San Francisco validating its Brainomix 360 e-Lung technology to identify progressive pulmonary f

Florida-based HCW Biologics first raised concerns about its financial sustainability over a year ago.\n Despite securing a much-needed $5 million lifeline from an equity offering this week, HCW Biologics is continuing to warn that its financial future remains in doubt.The inflammation-focused biotech explained in its first-quarter earnings release May 15 that the $1.1 million left in its bank account at the end of March meant there remained “substantial doubt” about the company’s ability

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including the 2025-2026 Best OTC Medicine & Health Products, Lilly's collaboration expansion with Purdue University, and a breakthrough in gene editing. NEW YORK, May 16, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular relea